Results 131 to 140 of about 577 (167)
Some of the next articles are maybe not open access.
SLEEP
Abstract Introduction The Epworth Sleepiness Scale (ESS) is a commonly used 8-item patient-reported outcome measure for excessive daytime sleepiness. While aggregate data are typically presented, individual domains vary in clinical significance.
Heidy Merius +5 more
openaire +2 more sources
Abstract Introduction The Epworth Sleepiness Scale (ESS) is a commonly used 8-item patient-reported outcome measure for excessive daytime sleepiness. While aggregate data are typically presented, individual domains vary in clinical significance.
Heidy Merius +5 more
openaire +2 more sources
SLEEP
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) demonstrated efficacy in treating narcolepsy symptoms, including disrupted nighttime sleep (DNS), in the phase 3 REST-ON trial (NCT02720744). This post hoc analysis assessed ON-SXB efficacy on DNS across various participant subgroups.
Yves Dauvilliers +7 more
openaire +2 more sources
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) demonstrated efficacy in treating narcolepsy symptoms, including disrupted nighttime sleep (DNS), in the phase 3 REST-ON trial (NCT02720744). This post hoc analysis assessed ON-SXB efficacy on DNS across various participant subgroups.
Yves Dauvilliers +7 more
openaire +2 more sources
SLEEP
Abstract Introduction Sodium oxybate, available in once-nightly and twice-nightly formulations, is indicated for treatment of cataplexy or excessive daytime sleepiness in narcolepsy. Once-nightly sodium oxybate extended-release oral suspension (ON-SXB; LUMRYZ™) may alleviate potential dosing ...
Maggie Lavender +5 more
openaire +2 more sources
Abstract Introduction Sodium oxybate, available in once-nightly and twice-nightly formulations, is indicated for treatment of cataplexy or excessive daytime sleepiness in narcolepsy. Once-nightly sodium oxybate extended-release oral suspension (ON-SXB; LUMRYZ™) may alleviate potential dosing ...
Maggie Lavender +5 more
openaire +2 more sources
SLEEP
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) is an extended-release formulation of sodium oxybate that eliminates the second, middle-of-the-night dose required by immediate-release twice-nightly oxybate (TN-OXB) formulations.
Sally Ibrahim +7 more
openaire +2 more sources
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) is an extended-release formulation of sodium oxybate that eliminates the second, middle-of-the-night dose required by immediate-release twice-nightly oxybate (TN-OXB) formulations.
Sally Ibrahim +7 more
openaire +2 more sources
SLEEP
Abstract Introduction In the phase 3 REST-ON clinical trial, extended-release, once-nightly sodium oxybate (ON-SXB) demonstrated a safety profile consistent with the known oxybate safety profile, with adverse drug reactions (ADRs) primarily related to tolerability.
Bruce Corser +8 more
openaire +2 more sources
Abstract Introduction In the phase 3 REST-ON clinical trial, extended-release, once-nightly sodium oxybate (ON-SXB) demonstrated a safety profile consistent with the known oxybate safety profile, with adverse drug reactions (ADRs) primarily related to tolerability.
Bruce Corser +8 more
openaire +2 more sources
SLEEP
Abstract Introduction Sodium oxybate (SXB) is a central nervous system depressant used to treat narcolepsy and has the potential to cause respiratory depression. Registrational trials of SXB have generally excluded patients with respiratory depression, including those with an apnea hypopnea index (AHI)
Richard Bogan +5 more
openaire +2 more sources
Abstract Introduction Sodium oxybate (SXB) is a central nervous system depressant used to treat narcolepsy and has the potential to cause respiratory depression. Registrational trials of SXB have generally excluded patients with respiratory depression, including those with an apnea hypopnea index (AHI)
Richard Bogan +5 more
openaire +2 more sources
Long-Term Safety of Once-Nightly Sodium Oxybate: Interim Analysis of Data From RESTORE (P5-13.005)
Neurology, 2023Thomas Stern +8 more
openaire +3 more sources